Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + eniluracil + fluorouracil
- Development stage
- Unknown
- Lead developer
- Adherex Technologies, Inc.
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of docetaxel, eniluracil, and fluorouracil (5-FU). Docetaxel promotes microtubule assembly, preventing cell division. Fluorouracil acts as an antimetabolite. Eniluracil inactivates dihydropyrimidine dehydrogenase (DPD), allowing for oral administration of 5-FU with predictable bioavailability. This combination has been studied primarily for the treatment of metastatic breast cancer.
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + eniluracil + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + eniluracil + fluorouracil.